Investment Thesis
LianBio is a pre-commercial pharmaceutical company burning cash at an unsustainable rate (-$53M FCF annually) against minimal revenue ($7.9M), with only ~2 years of cash runway at current burn levels despite a strong $103.5M cash position. While revenue growth is impressive percentage-wise and the balance sheet is unlevered, the company faces severe path-to-profitability challenges with extremely negative margins (-886% net margin) and stale financial data (September 2023) obscuring current status.
Strengths
- Strong balance sheet with $103.5M cash and zero debt exposure
- Exceptional liquidity position (10.06x current and quick ratios)
- Revenue growth of 1678% YoY demonstrates early commercial traction
- Minimal debt burden and low financial leverage risk
Risks
- Unsustainable cash burn of $53M annually relative to $7.9M revenue
- Extreme operating losses of $77.3M create multi-year profitability gap
- Estimated ~2 year cash runway at current burn rate
- Financial data severely outdated (September 2023, nearly 2.5 years old)
- Zero insider Form 4 activity in past 90 days suggests limited confidence
- Pre-commercial pharma stage with unproven drug pipeline viability
Key Metrics to Watch
- Operating cash flow trend and burn rate acceleration/deceleration
- Total cash balance depletion rate and months of runway remaining
- Revenue growth trajectory and gross margin development
- Capital raise activities and dilution impact
- Regulatory milestones and clinical trial advancement
Financial Metrics
Revenue
7.9M
Net Income
-69.7M
EPS (Diluted)
$-0.65
Free Cash Flow
-53.0M
Total Assets
262.9M
Cash
103.5M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-982.8%
Net Margin
-886.0%
ROE
-34.4%
ROA
-26.5%
FCF Margin
-674.2%
Balance Sheet & Liquidity
Current Ratio
10.06x
Quick Ratio
10.06x
Debt/Equity
0.00x
Debt/Assets
10.2%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-12T14:27:24.420324 |
Data as of: 2023-09-30 |
Powered by Claude AI